U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 3C18H34O2.2C6H14O6
Molecular Weight 1211.7276
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 3
Charge 0

SHOW SMILES / InChI
Structure of SORBITAN SESQUIOLEATE

SMILES

OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O

InChI

InChIKey=CUNWUEBNSZSNRX-RKGWDQTMSA-N
InChI=1S/3C18H34O2.2C6H14O6/c3*1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;2*7-1-3(9)5(11)6(12)4(10)2-8/h3*9-10H,2-8,11-17H2,1H3,(H,19,20);2*3-12H,1-2H2/b3*10-9-;;/t;;;2*3-,4+,5-,6-/m...11/s1

HIDE SMILES / InChI
Molecular Formula C18H34O2
Molecular Weight 282.4614
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE
Molecular Formula C6H14O6
Molecular Weight 182.1718
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

A sorbitol derivative emulsifier used in many topical agents. Sorbitan Sesquioleate is used in a variety of products including skin care products, skin cleansing products, moisturizers, eye makeup and other makeup, primarily as an emollient. It is added to formulas as a skin soother and moisturizer and is derived from sorbitol, a humectant. Sorbitol sesquioleate (SSO) have recently been implicated in allergic dermatitis.

Approval Year

1965
171
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Inactive ingredient
Approved
8429
Clobetasol propionate ointment

Approved Use

Clobetasol propionate cream and ointment are super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in children under 12 years of age is not recommended.

Launch Date

1996
PubMed

PubMed

TitleDatePubMed
Patents

Patents

US3656881
1
US4284630
1
US6680392
1
US8389640
1
US8778373
1

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 20:09:20 GMT 2023
Edited
by admin
on Sat Dec 16 20:09:20 GMT 2023
Record UNII
0W8RRI5W5A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SORBITAN SESQUIOLEATE
EP   II   INCI   INN   MART.   USAN   VANDF   WHO-DD  
INN   USAN   INCI  
Official Name English
SORBITAN SESQUIOLEATE [USAN]
Common Name English
SORBITAN SESQUIOLEATE [VANDF]
Common Name English
SORBITAN SESQUIOLEATE [INCI]
Common Name English
SORBITAN SESQUIOLEATE [EP MONOGRAPH]
Common Name English
SORBITAN SESQUIOLEATE [MART.]
Common Name English
SORBITAN SESQUIOLEATE [II]
Common Name English
SORBITAN SESQUIOLEATE [JAN]
Common Name English
SORBITAN SESQUIOLEATE [EP IMPURITY]
Common Name English
Sorbitan sesquioleate [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C83486
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C152407
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY
CAS
8007-43-0
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY
DAILYMED
0W8RRI5W5A
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY
MESH
C058854
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY
FDA UNII
0W8RRI5W5A
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY
RXCUI
1363058
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY RxNorm
INN
1877
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID6027682
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY
ECHA (EC/EINECS)
232-360-1
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY
EVMPD
SUB10600MIG
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY
PUBCHEM
6433515
Created by admin on Sat Dec 16 20:09:20 GMT 2023 , Edited by admin on Sat Dec 16 20:09:20 GMT 2023
PRIMARY
Related Record Type Details
Structure of Oleic acid
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966